Abnormal Genitalia/ Disorders of Sex Development Panel
Test code: EN0201
The Blueprint Genetics Abnormal Genitalia/ Disorders of Sex Development Panel is a 39 gene panel.
This panel is ideal for:
- Patients presenting with ambiguous genitalia
- Patients suspected to have a disorder of sexual development
- Patients suspected to have congenital adrenal hyperplasia not associated with CYP21A2 or CYP11B1
- Patients suspected to have congenital adrenal hyperplasia where previous CYP21A2 or CYP11B1 testing by non-NGS methods was negative for single nucleotide variants and insertions and deletions
Due to one or more regions of segmental duplication, this panel has reduced sensitivity to detect variants in exons 10-14 of ANOS1, exons 1-9 of CYP11B1 and exons 1-10 of CYP21A2.
Disorders of sex development (DSDs) and abnormal genitalia form a heterogenous group of conditions with various inheritance models. Inheritance of congenital adrenal hyperplasia (CAH) is autosomal recessive, while androgen insensitivity syndrome (AIS) is X-linked recessive. Approximately 1% of pathogenic variants causing CAH are de novo. In addition to primary DSD, this Panel have differential diagnostics power to several other rare diseases and syndromes that are characterized by abnormal genitalia.
About Abnormal Genitalia/ Disorders of Sex Development
Disorders of sex development (DSD) are a group of congenital conditions characterized by problems in the course of typical gender patterning, gonadal and sex development. It has been estimated that 1% – 2% of live births suffer from some aspects of DSD. Approximately 5% of infants with DSD have ambiguous genitalia and indeterminate sex at birth. However, the vast majority of these patiens never require corrective surgery. Patients with 46,XY DSD condition have often impaired androgen synthesis or action and may have normal female external genitalia, while patients with 46,XX DSD conditions have often androgen excess. In 46,XX females, congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21-OHD) is the most common cause of DSD. The estimated prevalence of CAH is 1:10 000 and 90%-95% of cases are due to mutations in CYP21A2. Severity of the phenotype often depends on the residual enzyme activity subdiving CYP21A2 mutations in severe (classic phenotype, enzyme activity 0%-10%) and mild (non-classic, enzyme activity 20%-50%) phenotypes. AIS caused by mutations in AR is characterized by feminization of external genitalia and abnormal sexual development in 46,XY individuals. The phenotype may be complete, partial or mild, depending on androgen insensitivity level. Mutations in the AR gene explain up to 95% of cases with complete androgen insensitivity, while for partial and mild subtypes the proportions are lower. The combined prevalence of various AIS subtypes is estimated to be 5:100 000.
Results in 3-4 weeks. We do not offer a maternal cell contamination (MCC) test at the moment. We offer prenatal testing only for cases where the maternal cell contamination studies (MCC) are done by a local genetic laboratory. Read more: http://blueprintgenetics.com/faqs/#prenatal
|AMH||Persistent Mullerian duct syndrome||AR||5||54|
|AMHR2||Persistent Mullerian duct syndrome||AR||6||33|
|ARX||Lissencephaly, Epileptic encephalopathy, Corpus callosum, agenesis of, with abnormal genitalia, Partington syndrome, Proud syndrome, Hydranencephaly with abnormal genitalia, Mental retardation||XL||64||85|
|ATRX||Carpenter-Waziri syndrome, Alpha-thalassemia/mental retardation syndrome, Holmes-Gang syndrome, Juberg-Marsidi syndrome, Smith-Fineman-Myers syndrome, Mental retardation-hypotonic facies syndrome||XL||54||155|
|BCOR||Microphthalmia, syndromic, Oculofaciocardiodental syndrome||XL||29||48|
|CDKN1C||Beckwith-Wiedemann syndrome, IMAGE syndrome||AD||24||81|
|CHD7||Isolated gonadotropin-releasing hormone deficiency, CHARGE syndrome||AD||192||784|
|CYP11B1*||Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, Glucocorticoid-remediable aldosteronism||AD/AR||24||132|
|CYP17A1||Adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiency||AR||35||120|
|CYP21A2*||Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, Hyperandrogenism, nonclassic , due to 21-hydroxylase deficiency||AR||45||299|
|DYNC2H1||Short -rib thoracic dysplasia with or without polydactyly type 1, Short -rib thoracic dysplasia with or without polydactyly type 3, Asphyxiating thoracic dysplasia (ATD; Jeune), SRPS type 2 (Majewski)||AR/Digenic||46||101|
|FIG4||Amyotrophic lateral sclerosis, Polymicrogyria, bilateral occipital, Yunis-Varon syndrome, Charcot-Marie-Tooth disease||AD/AR||26||58|
|GATA4||Tetralogy of Fallot, Atrioventricular septal defect, Testicular anomalies with or without congenital heart disease, Ventricular septal defect, Atrial septal defect||AD||36||120|
|HSD3B2||3-beta-hydroxysteroid dehydrogenase, II deficiency||AR||10||63|
|HSD17B3||17-Beta hydroxysteroid dehydrogenase III deficiency||AR||15||58|
|IRF6||Orofacial cleft, Popliteal pterygium syndrome, van der Woude syndrome||AD||36||336|
|LHCGR||Precocious puberty, male, Leydig cell hypoplasia, Luteinizing hormone resistance, female||AR||30||69|
|MKS1||Bardet-Biedl syndrome, Meckel syndrome||AR||42||51|
|NR5A1||Adrenocortical insufficiency, Premature ovarian failure, 46,XY sex reversal||AD/AR||26||165|
|NR0B1||Adrenal hypoplasia, congenital, 46,XY sex reversal||XL||59||247|
|POR||Disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency, Antley-Bixler syndrome||AR||12||67|
|RSPO1||Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,XX sex reversal||AR||3||3|
|SOX9||Campomelic dysplasia, 46,XY sex reversal, Brachydactyly with anonychia (Cooks syndrome)||AD||34||139|
|SRD5A2||Steroid 5-alpha-reductase 2 deficiency||AR||24||119|
|SRY||46,XX disorder of sex development, 46,XY disorder of sex development||YL||24||106|
|STAR||Lipoid adrenal hyperplasia||AR||16||81|
|WT1||Denys-Drash syndrome, Frasier syndrome, Wilms tumor||AD||29||172|
|ZFPM2||46,XY sex reversal||AD||8||44|
*Some regions of the gene are duplicated in the genome leading to limited sensitivity within the regions. Thus, low-quality variants are filtered out from the duplicated regions and only high-quality variants confirmed by other methods are reported out. Read more.
Gene, refers to HGNC approved gene symbol; Inheritance to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR) and X-linked (XL); ClinVar, refers to a number of variants in the gene classified as pathogenic or likely pathogenic in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/); HGMD, refers to a number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/). The list of associated (gene specific) phenotypes are generated from CDG (http://research.nhgri.nih.gov/CGD/) or Orphanet (http://www.orpha.net/) databases.
|Gene||Genomic location HG19||HGVS||RefSeq||RS-number|
The strengths of this test include:
- Blueprint Genetics is one of the few laboratories worldwide with CAP and ISO-15189 accreditation for NGS panels and CLIA certification
- Superior sequencing quality
- Careful selection of genes based on current literature, our experience and the most current mutation databases
- Transparent and easy access to quality and performance data at the patient level that are accessible via our Nucleus portal
- Transparent and reproducible analytical validation for each panel (see Test performance section; for complete details, see our Analytic Validation)
- Sequencing and high resolution del/dup analysis available in one test
- Inclusion of non-coding disease causing variants where clinically indicated (please see individual Panel descriptions)
- Interpretation of variants following ACMG variant classification guidelines
- Comprehensive clinical statement co-written by a PhD geneticist and a clinician specialist
This test does not detect the following:
- Fusion of CYP11B1 and CYP11B2 associated with glucocorticoid-remediable aldosteronism
- Complex inversions
- Gene conversions
- Balanced translocations
- Mitochondrial DNA variants
- Variants in regulatory or non-coding regions of the gene unless otherwise indicated (please see Non-coding disease causing variants covered by the panel). This mean for instance intronic variants locating deeper than 15 nucleotides from the exon-intron boundary.
This test may not reliably detect the following:
- Due to one or more regions of segmental duplication, this panel has reduced sensitivity to detect variants in exons 10-14 of ANOS1, exons 1-9 of CYP11B1 and exons 1-10 of CYP21A2.
- Low level mosaicism
- Stretches of mononucleotide repeats
- Indels larger than 50bp
- Single exon deletions or duplications
- Variants within pseudogene regions/duplicated segments
- Disorders caused by long repetitive sequences (e.g. trinucleotide repeat expansions)
The sensitivity of this test may be reduced if DNA is extracted by a laboratory other than Blueprint Genetics.
For additional information, please refer to the Test performance section and see our Analytic Validation.
Blueprint Genetics offers a comprehensive Abnormal Genitalia/ Disorders of Sex Development Panel that covers classical genes associated with androgen insensitivity syndrome, congenital adrenal hyperplasia, female pseudohermaphroditism, indeterminate sex and pseudohermaphroditism, male pseudohermaphroditism and persistent Mullerian duct syndrome. The genes are carefully selected based on the existing scientific evidence, our experience and most current mutation databases. Candidate genes are excluded from this first-line diagnostic test. The test does not recognise balanced translocations or complex inversions, and it may not detect low-level mosaicism. The test should not be used for analysis of sequence repeats or for diagnosis of disorders caused by mutations in the mitochondrial DNA.
Analytical validation is a continuous process at Blueprint Genetics. Our mission is to improve the quality of the sequencing process and each modification is followed by our standardized validation process. Average sensitivity and specificity in Blueprint NGS Panels is 99.3% and 99.9% for detecting SNPs. Sensitivity to for indels vary depending on the size of the alteration: 1-10bps (96.0%), 11-20 bps (88.4%) and 21-30 bps (66.7%). The longest detected indel was 46 bps by sequence analysis. Detection limit for Del/Dup (CNV) analysis varies through the genome depending on exon size, sequencing coverage and sequence content. The sensitivity is 71.5% for single exon deletions and duplications and 99% for three exons’ deletions and duplications. We have validated the assays for different starting materials including EDTA-blood, isolated DNA (no FFPE) and saliva that all provide high-quality results. The diagnostic yield varies substantially depending on the used assay, referring healthcare professional, hospital and country. Blueprint Genetics’ Plus Analysis (Seq+Del/Dup) maximizes the chance to find molecular genetic diagnosis for your patient although Sequence Analysis or Del/Dup Analysis may be cost-effective first line test if your patient’s phenotype is suggestive for a specific mutation profile.
The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. The highest relevance in the reported variants is achieved through elimination of false positive findings based on variability data for thousands of publicly available human reference sequences and validation against our in-house curated mutation database as well as the most current and relevant human mutation databases. Reference databases currently used are the 1000 Genomes Project (http://www.1000genomes.org), the NHLBI GO Exome Sequencing Project (ESP; http://evs.gs.washington.edu/EVS), the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org), ClinVar database of genotype-phenotype associations (http://www.ncbi.nlm.nih.gov/clinvar) and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk). The consequence of variants in coding and splice regions are estimated using the following in silico variant prediction tools: SIFT (http://sift.jcvi.org), Polyphen (http://genetics.bwh.harvard.edu/pph2/), and Mutation Taster (http://www.mutationtaster.org).
Through our online ordering and statement reporting system, Nucleus, the customer can access specific details of the analysis of the patient. This includes coverage and quality specifications and other relevant information on the analysis. This represents our mission to build fully transparent diagnostics where the customer gains easy access to crucial details of the analysis process.
In addition to our cutting-edge patented sequencing technology and proprietary bioinformatics pipeline, we also provide the customers with the best-informed clinical report on the market. Clinical interpretation requires fundamental clinical and genetic understanding. At Blueprint Genetics our geneticists and clinicians, who together evaluate the results from the sequence analysis pipeline in the context of phenotype information provided in the requisition form, prepare the clinical statement. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals, even without training in genetics.
Variants reported in the statement are always classified using the Blueprint Genetics Variant Classification Scheme modified from the ACMG guidelines (Richards et al. 2015), which has been developed by evaluating existing literature, databases and with thousands of clinical cases analyzed in our laboratory. Variant classification forms the corner stone of clinical interpretation and following patient management decisions. Our statement also includes allele frequencies in reference populations and in silico predictions. We also provide PubMed IDs to the articles or submission numbers to public databases that have been used in the interpretation of the detected variants. In our conclusion, we summarize all the existing information and provide our rationale for the classification of the variant.
A final component of the analysis is the Sanger confirmation of the variants classified as likely pathogenic or pathogenic. This does not only bring confidence to the results obtained by our NGS solution but establishes the mutation specific test for family members. Sanger sequencing is also used occasionally with other variants reported in the statement. In the case of variant of uncertain significance (VUS) we do not recommend risk stratification based on the genetic finding. Furthermore, in the case VUS we do not recommend use of genetic information in patient management or genetic counseling. For some cases Blueprint Genetics offers a special free of charge service to investigate the role of identified VUS.
We constantly follow genetic literature adapting new relevant information and findings to our diagnostics. Relevant novel discoveries can be rapidly translated and adopted into our diagnostics without delay. These processes ensure that our diagnostic panels and clinical statements remain the most up-to-date on the market.
Choose an analysis method
ICD & CPT codes
Commonly used ICD-10 codes when ordering the Abnormal Genitalia/ Disorders of Sex Development Panel
|Q56.0||Indeterminate sex and pseudohermaphroditism|
|E34.50||Androgen insensitivity syndrome|
|E25.0||Congenital adrenal hyperplasia|
Accepted sample types
- EDTA blood, min. 1 ml
- Purified DNA, min. 5μg
- Saliva (Oragene DNA OG-500 kit)
Label the sample tube with your patient’s name, date of birth and the date of sample collection.
Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.